2016
Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study
Valenzuela A, Baron M, Group C, Herrick AL, Proudman S, Stevens W, Group A, Rodriguez-Reyna TS, Vacca A, Medsger TA, Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars In Arthritis And Rheumatism 2016, 46: 344-349. PMID: 27371996, PMCID: PMC5500288, DOI: 10.1016/j.semarthrit.2016.05.008.Peer-Reviewed Original ResearchMeSH KeywordsAcro-OsteolysisAdultAgedAntibodies, AntinuclearAutoantibodiesCalcinosisCohort StudiesDNA Topoisomerases, Type IFemaleFingersHeart DiseasesHumansHypertension, PulmonaryLogistic ModelsMaleMiddle AgedMultivariate AnalysisNuclear ProteinsOdds RatioOsteoporosisRetrospective StudiesRibonucleoprotein, U1 Small NuclearRNA Polymerase IIIScleroderma, SystemicSkin UlcerTelangiectasisConceptsScleroderma Clinical Trials ConsortiumDigital ulcersSystemic sclerosisOdds ratioMultivariate analysisAnti-PM/SclRetrospective cohort studyQuarter of patientsLonger disease durationClinical Trials ConsortiumStrong associationMulticenter collaborative effortsGastrointestinal involvementAnticardiolipin antibodiesPulmonary hypertensionCohort studyDisease durationClinical factorsAcro-osteolysisClinical featuresUnivariate analysisCardiac diseasePatientsCalcinosisUlcers
2008
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.Peer-Reviewed Original ResearchConceptsInternal organ involvementSystemic sclerosisOrgan involvementRaynaud's phenomenonEndothelin-1 receptor blockerChronic connective tissue diseaseEnd-organ dysfunctionEnzyme inhibitor therapyHigh-dose corticosteroidsScleroderma renal crisisPulmonary arterial hypertensionPulmonary function testingConnective tissue diseaseDisease-modifying therapiesDistinct clinical subsetInternal organ dysfunctionOrgan-specific manifestationsPhosphodiesterase-5 inhibitorsMiddle-age womenOptimal patient careWidespread microvascular damageRenal crisisArterial hypertensionDigital ulcersLifestyle modification